Full Press Release Details
Second Quarter 2020 Financial Results
N.J., August 10, 2020 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for
the second quarter ended June 30, 2020 and provided a corporate update.
and Recent Corporate Highlights
"We continue to enroll relapsed/refractory
multiple myeloma and LPL/WM patients in the Phase 2b portion of our ongoing CLOVER-1 study and prepare for the initiation of our
pivotal study expected in Q4 of 2020 while advancing our Phase 1 pediatric study " said James Caruso, president and CEO of
Cellectar. "We also successfully executed on other key fronts. The FDA granted CLR 131 Fast Track Designation in LPL/WM;
we expanded our IP portfolio with two new European patents and significantly strengthened our balance sheet with the recent financing."
2020 Financial Highlights
Cellectar Biosciences is focused on the
discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs
independently and through research and development collaborations. The company's core objective is to leverage its proprietary
Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved
efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for
the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently
and through research and development collaborations.
The company's lead PDC therapeutic,
CLR 131, is currently in two clinical studies. The CLOVER-1 Phase 2 study completed the Part A dose-exploration portion, conducted
in relapsed/refractory (r/r) B-cell malignancies, and is now enrolling in the Part B expansion cohorts evaluating a two cycle dosing
regimen that provides approximately 100mCi total body dose of CLR 131 in relapsed/refractory (r/r) multiple myeloma (MM) and lymphoplasmacytic
lymphoma/Waldenstrom's macroglobulinemia (LPL/WM). The data from the Part A portion was announced on February 19, 2020.
The Phase 1 pediatric study is an open-label,
sequential-group, dose-escalation study to evaluate the safety and tolerability of CLR 131 in children and adolescents with relapsed
or refractory cancers, including malignant brain tumors, neuroblastoma, sarcomas, and lymphomas (including Hodgkin's lymphoma).
The Phase 1 study is being conducted internationally at 7 leading pediatric cancer centers.
The company's product pipeline includes
one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.
For more information, please visit
www.cellectar.com or join the conversation by liking and following us on the company's
social media channels: Twitter, LinkedIn, and
Statement Disclaimer
news release contains forward-looking statements. You can identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate," "continue,"
"plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known
and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements
made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations
of the impact of the recent COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might
cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties
related to the disruptions at our sole source supplier of CLR 131, the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of
clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the
United States for CLR 131, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully
develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.
A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities
and Exchange Commission including our Form 10-K for the year ended December 31, 2019, our Form 10-Q for the quarter ended March
31, 2020 and our Form 10-Q for the quarter ended June 30, 2020, when filed. These forward-looking statements are made only as of
the date hereof, and we disclaim any obligation to update any such forward-looking statements. These forward-looking statements
are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.
LifeSci Advisors, LLC
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2020 (Unaudited) | December 31, 2019 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 22,450,203 | $ | 10,614,722 | ||||
| Prepaid expenses and other current assets | 593,590 | 770,951 | ||||||
| Total current assets | 23,043,793 | 11,385,673 | ||||||
| Fixed assets, net | 410,624 | 435,083 | ||||||
| Right-of-use asset, net | 316,917 | 348,841 | ||||||
| Long-term assets | 81,214 | 75,000 | ||||||
| Other assets | - | 6,214 | ||||||
| TOTAL ASSETS | $ | 23,852,548 | $ | 12,250,811 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable and accrued liabilities | $ | 3,207,041 | $ | 2,663,873 | ||||
| Lease liability | 112,713 | 105,885 | ||||||
| Total current liabilities | 3,319,754 | 2,769,758 | ||||||
| LONG-TERM LIABILITIES: | ||||||||
| Lease liability | 363,534 | 421,644 | ||||||
| Loan payable | 184,000 | - | ||||||
| Total long-term liabilities | 547,534 | 421,644 | ||||||
| TOTAL LIABILITIES | 3,867,288 | 3,191,402 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 7) | ||||||||
| STOCKHOLDERS' EQUITY: | ||||||||
| Preferred stock, $0.00001 par value; 7,000 shares authorized; Series C preferred stock: 215 issued and outstanding as of June 30, 2020 and December 31, 2019 | 1,148,204 | 1,148,204 | ||||||
| Common stock, $0.00001 par value; 80,000,000 shares authorized; 25,472,383 and 9,386,689 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively | 254 | 94 | ||||||
| Additional paid-in capital | 138,087,590 | 119,592,366 | ||||||
| Accumulated deficit | (119,250,788 | ) | (111,681,255 | ) | ||||
| Total stockholders' equity | 19,985,260 | 9,059,409 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 23,852,548 | $ | 12,250,811 |
CELLECTAR BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| COSTS AND EXPENSES: | ||||||||||||||||
| Research and development | $ | 2,465,392 | $ | 1,809,547 | $ | 5,081,729 | $ | 4,117,944 | ||||||||
| General and administrative | 1,156,842 | 1,390,812 | 2,499,160 | 2,712,227 | ||||||||||||
| Total costs and expenses | 3,622,234 | 3,200,359 | 7,580,889 | 6,830,171 | ||||||||||||
| LOSS FROM OPERATIONS | (3,622,234 | ) | (3,200,359 | ) | (7,580,889 | ) | (6,830,171 | ) | ||||||||
| OTHER INCOME: | ||||||||||||||||
| Gain/(Loss) on revaluation of derivative warrants | - | 1,000 | - | (3,000 | ) | |||||||||||
| Interest income, net | 10,309 | 11,798 | 11,356 | 23,969 | ||||||||||||
| Total other income | 10,309 | 12,798 | 11,356 | 20,969 | ||||||||||||
| NET LOSS | $ | (3,611,925 | ) | $ | (3,187,561 | ) | $ | (7,569,533 | ) | $ | (6,809,202 | ) | ||||
| BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE | $ | (0.26 | ) | $ | (0.46 | ) | $ | (0.65 | ) | $ | (1.15 | ) | ||||
| SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE | 13,793,548 | 6,963,301 | 11,591,605 | 5,935,111 |